Bilimsel Makale Arama | NeuralCipher AI

Kaynak kaydı

The Influence of Gut Microbiome on Alpha-Synuclein Aggregation: Implications for Parkinson's Disease Pathogenesis.

Sain M, Rani S, Singh SP, Pothal P, Yadav S, Suttee A, Kumar A, Kumar S, Ranawat P, Singh G, Barnwal RP.

Mol Neurobiol · 2026-05-19

DOI: 10.1007/s12035-026-05917-6PMID: 42154337

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Açık erişim

PRKN/parkin-mediated control of SNCA (synuclein alpha) and chaperone-mediated autophagy are defective in cellular, mice models and Parkinson disease-affected brains.

Ramos Dos Santos L, Duplan E, Debord J, Fremont G, Minniti J, Lauritzen I, Mutez E, Leghay C, Chartier-Harlin MC, Checler F, Alves da Costa C.

Autophagy · 2026-05-13

DOI: 10.1080/15548627.2026.2669458PMID: 42083315

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Açık erişim

Molecular profiling of alpha-synuclein pathology and seeding activity in Parkinson's disease.

Kaya ZB, Amerna D, Susarla A, Lim MJ, Bregendahl M, Sekiya H, DeTure M, Ross OA, Dickson DW, Boschen SL, McLean PJ.

Acta Neuropathol · 2026-05-12

DOI: 10.1007/s00401-026-03026-1PMID: 42118167

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Kaynak kaydı

How PPMI Enabled the First Interventional Platform Trial to Test Therapies in Participants With Early-Stage Neuronal Alpha-Synuclein Disease.

Simuni T, Coffey CS, Kopil CM, Allen-Savietta C, Wendelberger B, Crawford A, Schneider RB, Siderowf A, Kieburtz K, Tanner CM, Tropea TF, Whalen H, Ramia L, Kamp C, Reyes C, Fabrizio K, Willson T, Merriam E, Kuhl MM, Chowdhury S, Marek K, Parkinson's Progression Markers Initiative.

Ann Neurol · 2026-05-07

DOI: 10.1002/ana.78250PMID: 42095573

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Kaynak kaydı

Beyond Amyloids: Neuroprotective Potential of Betanin and its Derivatives Against Alpha-Synuclein Aggregates and ROS Overload in Parkinson's Disease.

Ghahari A, Alikhanian A, Solaei FA, Fattahi A, Hourfar H, Schallmey A, Mohammadi M, Morshedi D.

J Mol Neurosci · 2026-05-04

DOI: 10.1007/s12031-026-02534-9PMID: 42081152

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Kaynak kaydı

Targeting Alpha-Synuclein Aggregation With Chemical Chaperone IP-045: An Approach to Parkinson's Disease Therapy.

Kaur N, Singh R, Dhingra N, Kaur T.

Drug Dev Res · 2026-05-01

DOI: 10.1002/ddr.70288PMID: 42003184

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Açık erişim

Selective vulnerability of monoaminergic neurons and network spread of alpha-synuclein jointly explain pathology progression in Parkinson's disease models.

Teshome S, Torok J, Mezias C, Gupta A, Raj A.

Neurobiol Dis · 2026-04-27

DOI: 10.1016/j.nbd.2026.107403PMID: 42055257

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Açık erişim

Single-molecule detection methods to study alpha-synuclein aggregation in postmortem Parkinson's disease brains.

Fertan E, Danial JSH, Neame S, Lam JYL, Cotton MW, Burke M, Xia Z, Wu Y, Powney B, Imaizumi Y, Quaegebeur A, Meisl G, Staddon J, Klenerman D.

Cell Rep Methods · 2026-04-23

DOI: 10.1016/j.crmeth.2026.101418PMID: 42030949

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Kaynak kaydı

Rab27b: A Modulator of Lysosomal Function and Alpha-Synuclein Clearance in Parkinson's Disease.

Badell-Grau RA.

J Neurosci · 2026-04-22

DOI: 10.1523/jneurosci.0917-25.2026PMID: 42020315

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Açık erişim

Clinical Progression in Alpha-Synuclein Positive LRRK2-PD and Sporadic Parkinson's Disease: A Longitudinal Analysis.

Morse LA, Choi SH, Gochanour C, Lafontant DE, Chahine LM, Merchant KM, Wendelberger B, Simuni T, Parkinson's Progression Markers Initiative.

Mov Disord Clin Pract · 2026-04-19

DOI: 10.1002/mdc3.70640PMID: 42003081

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Açık erişim

Synergistic Effects of Multi-Kinase Inhibition on <i>LRRK2</i>-G2019S and Alpha-Synuclein Pathologies in Models of Parkinson's Disease.

Liu X, Baxley S, Hebron ML, Moussa C.

Biomedicines · 2026-04-18

DOI: 10.3390/biomedicines14040927PMID: 42072468

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Açık erişim

Shared Epitope-Positive <i>HLA</i> Alleles Protect Against Alpha-Synuclein Pathology in a Model of Parkinson Disease.

Carver JJ, Pugh BA, Ma Q, Caillier SJ, Denbrock RR, Martines CC, Puckett AE, Roberson TC, Fernandez-Viña MA, Hollenbach JA, Oksenberg J, Holoshitz J, Didonna A.

Neurol Neuroimmunol Neuroinflamm · 2026-04-17

DOI: 10.1212/nxi.0000000000200580PMID: 41996655

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Kayıtlar bilimsel kaynaklardan alınır. Bibliyografik kayıt sayısı, Türkçe çeviri veya editoryal onay sayısı değildir.

715 makale bulundu

The Influence of Gut Microbiome on Alpha-Synuclein Aggregation: Implications for Parkinson's Disease Pathogenesis.

PRKN/parkin-mediated control of SNCA (synuclein alpha) and chaperone-mediated autophagy are defective in cellular, mice models and Parkinson disease-affected brains.

Molecular profiling of alpha-synuclein pathology and seeding activity in Parkinson's disease.

How PPMI Enabled the First Interventional Platform Trial to Test Therapies in Participants With Early-Stage Neuronal Alpha-Synuclein Disease.

Beyond Amyloids: Neuroprotective Potential of Betanin and its Derivatives Against Alpha-Synuclein Aggregates and ROS Overload in Parkinson's Disease.

Targeting Alpha-Synuclein Aggregation With Chemical Chaperone IP-045: An Approach to Parkinson's Disease Therapy.

Selective vulnerability of monoaminergic neurons and network spread of alpha-synuclein jointly explain pathology progression in Parkinson's disease models.

Single-molecule detection methods to study alpha-synuclein aggregation in postmortem Parkinson's disease brains.

Rab27b: A Modulator of Lysosomal Function and Alpha-Synuclein Clearance in Parkinson's Disease.

Clinical Progression in Alpha-Synuclein Positive LRRK2-PD and Sporadic Parkinson's Disease: A Longitudinal Analysis.

Synergistic Effects of Multi-Kinase Inhibition on <i>LRRK2</i>-G2019S and Alpha-Synuclein Pathologies in Models of Parkinson's Disease.

Shared Epitope-Positive <i>HLA</i> Alleles Protect Against Alpha-Synuclein Pathology in a Model of Parkinson Disease.

Filtreler